Zealand Pharma and Boehringer Ingelheim’s weight-loss drug meets goals in mid-stage trial

Denmark’s Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up
a potential contestant in the booming obesity drug market.

In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks.

Paola Casarosa, head of therapeutic areas at Germany’s Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a
planned follow-up trial in the third and last phase of testing.

The enormous demand for weight-loss treatments such as Novo Nordisk’s Wegovy, or potentially Eli Lilly’s Mounjaro, could support as many as 10 competing products
with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.

Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.